Boan Biotech to Present New Preclinical Data for CD3/CEA BsAb at AACR 2021

Boan Biotech, a holding subsidiary of Luye Pharma Group, will present an abstract about the preclinical data on its CD3/CEA bispecific antibody program at the American Association for Cancer Research (AACR) Annual Meeting 2021. 

The historic AACR Annual Meeting is one of the world’s largest academic conferences related to cancer research, covering the latest discoveries across the spectrum and highlighting the work of the best minds in research and medicine from institutions all over the world. The meeting will be held virtually from April 10-15, and May 17-21 this year at Eastern Standard Time. 

Details of the project presented by Boan Biotech are as follows:

Title: An optimized tetravalent bispecific T cell engager for CEA with increased therapeutic index
Abstract Control Number: 4534
Session Title: Therapeutic Antibodies, Including Engineered Antibodies

Background

Immunotherapies utilizing T cell-dependent bispecific antibodies have revolutionized cancer treatment. CD3-based bispecific T cell engagers (BsTCE) are one of the most promising antibody formats for the development of novel and effective cancer treatments. 
The anti-CEA/anti-CD3 BsAb (BA1202) is an innovative drug candidate of Boan Biotech. The drug has been developed based on the leading bispecific T-cell Engager platform with independent intellectual property rights owned by Boan Biotech. Pre-clinical research data show that the optimized anti-CEA/anti-CD3 BsAb reduces cytokine release, making it possible to reduce the cytokine storm while improving the efficacy of the product, indicating better treatment options for patients with solid tumors in clinical trials.
Dr. Zhou Li, Vice President of Antibody Research at Boan Biotech, said, “We are delighted that the preclinical data of our latest drug candidate is being accepted by the AACR Annual Meeting this year. As a fully-integrated biopharmaceutical company, we specialize in therapeutic antibody development and conduct pioneering research in the frontiers of science. We plan to explore further innovative and prospective therapies to meet the clinical needs of patients. "